What are disease modifying therapies (DMTs) and what impact could they have for people living with Parkinson’s?

In this episode, we delve into the evolving world of DMTs, exploring their potential to slow, halt, or even reverse the progression of Parkinson's, and the challenges involved in bringing these therapies to fruition.

We hear from Philippe, who shares his personal journey with the condition and his thoughts on what it means to slow its progression.

Joining him is Kate Trenam, a Senior Director at the global biopharma company UCB, who provides expert insights into current research, global collaboration efforts, and how DMTs could one day change the way Parkinson’s is treated.

We explore the challenges of measuring the effectiveness of DMTs, the importance of global representation in clinical studies, and why continued patient participation in research is critical to progress.

Meet your hosts:

Amelia Hersey is Research Manager at Parkinson's Europe. She has a master's in cognitive neuropsychology and has been involved in the neurodegenerative research world for 15 years.

Anthony Zahra is a broadcaster and journalist with more than 20 years’ experience in radio, digital and podcasting.

For the latest research and information on Parkinson’s, visit the Parkinson's Europe website.

If you like what you’ve heard, please rate and review – it helps make sure others can find us. Keep a lookout for our next episode and until then, take care!

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we explore deep brain stimulation (DBS) and the impact it can have on people with Parkinson’s.

Gerlach Roomans was diagnosed in 2009 and decided to have a DBS procedure after a discussion with his neurologist.

He describes how he felt in the lead up to the operation, the experience of DBS itself, and how it has affected his life since.

He is joined by Lucy Partington-Smith, a DBS and advanced therapy nurse specialist in Manchester in the UK.

And Veerle Visser-Vandewalle, a neurosurgeon and Head of the Department of Stereotactic and Functional Neurosurgery at the University of Cologne.

Together, they discuss all aspects of DBS from how it is decided whether it is suitable for a patient, the risks associated, some of the potential side effects, and the ongoing support that is provided after the initial surgery.

For the latest research and information on Parkinson’s, visit the Parkinson's Europe website.

If you like what you’ve heard, please rate and review – it helps make sure others can find us. Keep a lookout for our next episode and until then, take care!

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we look at the role that technology can play in supporting people with Parkinson’s.

UK-based Elaine Payne shares how she uses digital devices to help manage her Parkinson’s symptoms – and why she encourages those with the condition to connect with others in the community.

She talks to Dr Alistair Mackett, a consultant geriatrician at Addenbrooke’s Hospital in Cambridge, UK, who sheds light on some of the tools and resources available.

Joining them is Lucy Jung, CEO of technology company Charco Neurotech, who highlights the impact that digital support can have for both clinicians and people with Parkinson’s.

Together, our guests explore the challenges and opportunities of implementing technology into management strategies – and look at possible future developments in this area.

This podcast is sponsored by Charco Neurotech, the technology company behind the CUE devices – wearable medical tools designed to support movement in people with Parkinson’s. The episode represents the individual views and experiences of the podcast attendees.

For the latest research and information on Parkinson’s, visit www.parkinsonseurope.org.

If you like what you’ve heard, please rate and review – it helps make sure others can find us. Keep a lookout for our next episode and until then, take care!

Hosted on Acast. See acast.com/privacy for more information.